Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-08-2005 | Article

Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups

Authors: K. Caglar, R. Karakus, C. Aybay

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2005

Abstract

In this study, tetanus immunity was determined in 549 randomly chosen individuals of various age groups in Ankara, Turkey. Antibody levels in sera of the individuals were measured using a double-antigen enzyme-linked immunosorbent assay. Overall, 66.5% (95%CI, 62.4–70.4) of the population studied was found to have basic protection (≥0.01 IU/ml) against tetanus. Protective levels of tetanus antibodies declined progressively with age. The rate of protection in children and adolescents (aged <20 years) exceeded 90%, while only 16.3% (95%CI, 8.9–26.2) of those over 60 years of age were protected. Females over 60 years of age were less immune than males of the same age group (p=0.034). Although the rates of protection in children and adolescents are regarded as satisfactory, the rates among adults are low. Preventive measures against tetanus should therefore focus on scheduled booster immunization for adults as well as children.

Oladiran I, Meier DE, Ojelade AA, OlaOlarun DA, Adeniran A, Tarpley JL (2002) Tetanus: continuing problem in the developing world. World J Surg 26:1282–1285CrossRefPubMed

Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S (2003) Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 21:3442–3445CrossRefPubMed

Ergonul O, Erbay A, Eren S, Dokuzoguz B (2003) Analysis of the case fatality rate of tetanus among adults in a tertiary hospital in Turkey. Eur J Clin Microbiol Infect Dis 22:188–190

Galazka AM (1993) The immunological basis for immunization series. Module 3: tetanus. Document no. WHO/EPI/GEN/93.13. World Health Organization, Geneva

Deming MS, Roungou JB, Kristiansen M, Heron I, Yango A, Guenengafo A, Ndamobissi R (2002) Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus. Bull World Health Organ 80:696–703PubMed

de la Chapelle A, Lavabre O, Pinsard M, Delamonica J, Relyveld EH (2002) Tetanus in a renal transplant recipient exhibiting the presence of circulating antitetanus antibodies determined by ELISA. Biomed Pharmacother 56:208–210CrossRefPubMed

Crone NE, Reder AT (1992) Severe tetanus in immunized patients with high antitetanus titres. Neurology 42:761–764PubMed

Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G (1995) A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 332:761–766CrossRefPubMed

Heath TC, Smith W, Capon AG, Hanlon M, Mitchell P (1996) Tetanus immunity in an older Australian population. Med J Aust 164:593–596PubMed

10.

Kruszon-Moran DM, McQuillan GM, Chu SY (2004) Tetanus and diphtheria immunity among females in the United States: are recommendations being followed? Am J Obstet Gynecol 190:1070–1076CrossRefPubMed

11.

McQuillan GM, Kruszon-Moran DM, Deforest A, Chu SY, Wharton M (2002) Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 136:660–666PubMed

12.

Brabin L, Fazio-Tirrozzo G, Shahid S, Agbaje O, Maxwell S, Broadhead R, Briggs N, Brabin B (2000) Tetanus antibody levels among adolescent girls in developing countries. Trans R Soc Trop Med Hyg 94:455–459CrossRefPubMed

13.

Vogel M, Lai L, Rudolf MP, Curcio-Vonlanthen V, Miescher S, Stadler BM (1996) Cross-reactive antitetanus and antimelittin Fab fragments by phage display after tetanus toxoid immunization. Hum Antibodies Hybridomas 7:11–20PubMed

14.

Elm J, Desowitz R, Diwan A (1998) Serological cross-reactivities between the retroviruses HIV and HTLV-1 and the malaria parasite Plasmodium falciparum. P N G Med J 41:15–22PubMed

15.

Magnarelli LA, Anderson JF, Johnson RC (1987) Cross-reactivity in serological tests for Lyme disease and other spirochetal infections. J Infect Dis 156:183–188PubMed

16.

Sood SK, Rubin LG, Blader ME, Ilowite NT (1993) Positive serology for Lyme borreliosis in patients with juvenile rheumatoid arthritis in a Lyme borreliosis endemic area: analysis by immunoblot. J Rheumatol 20:739–741PubMed

17.

Keymeulen B, Somers G, Naessens A, Verbruggen LA (1993) False-positive ELISA serologic test for Lyme borreliosis in patients with connective tissue diseases. Clin Rheumatol 12:526–528PubMed

18.

Weiss NL, Sadock VA, Sigal LH, Phillips M, Merryman PF, Abramson SB (1995) False-positive seroreactivity to Borrelia burgdorferi in systemic lupus erythematosus: the value of immunoblot analysis. Lupus 4:131–137PubMed

19.

Wilson M, Remington JS, Clavet C, Varney G, Press C, Ware D (1997) Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol 35:3112–3115

20.

Palosuo T, Aho K (1983) Technical falsely positive rheumatoid factor by ELISA in sera with elevated IgM levels. Med Biol 61:203–207PubMed

21.

Martins TB, Jaskowski TD, Mouritsen CL, Hill HR (1995) An evaluation of the effectiveness of three immunoglobulin G (IgG) removal procedures for routine IgM serological testing. Clin Diagn Lab Immunol 2:98–103PubMed

22.

Bouillon M, Aubin E, Roberge C, Bazin R, Lemieux R (2002) Reduced frequency of blood donors with false-positive HIV-1 and -2 antibody EIA reactivity after elution of low-affinity nonspecific natural antibodies. Transfusion 42:1046–1052CrossRefPubMed

23.

Simonsen O, Bentzon MW, Heron I (1986) ELISA for the routine determination of antitoxic immunity to tetanus. J Biol Stand 14:231–239

24.

Hendriksen CF, van der Gun JW, Nagel J, Kreeftenberg JG (1988) The toxin binding inhibition test as a reliable in vitro alternative to the toxin neutralization test in mice for the estimation of tetanus antitoxin in human sera. J Biol Stand 16:287–297

25.

Kristiansen M, Aggerbeck H, Heron I (1997) Improved ELISA determination of antidiphtheria and/or antitetanus antitoxin antibodies in sera. APMIS 105:843–853PubMed

26.

Bieber F (1992) Biotinylating monoclonal antibodies. In: Peters JH, Baumgarten H (eds) Monoclonal antibodies. Springer-Verlag, Heidelberg, pp 299–303

27.

Danilova E, Shiryayev A, Skogen V, Kristoffersen EK, Sjursen H (2005) Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine 23:1446–1450CrossRefPubMed

28.

Bonetti TC, Succi RC, Weckx LY, Tavares-Lopes L, de Moraes-Pinto MI (2004) Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 22:3707–3712CrossRefPubMed

29.

Olander RM, Wuorimaa T, Kayhty H, Leroy O, Dagan R, Eskola J (2001) Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers. Vaccine 20:336–341CrossRefPubMed

30.

Ergonul O, Sozen T, Tekeli E (2001) Immunity to tetanus among adults in Turkey. Scand J Infect Dis 33:728–730CrossRefPubMed

31.

Kurtoglu D, Gozalan A, Coplu N, Miyamura K, Morita M, Esen B, Akin L (2004) Community-based seroepidemiology in three selected provinces in Turkey. Jpn J Infect Dis 57:10–16PubMed

32.

Maple PAC, Jones CS, Wall EC, Vyse A, Edmunds WJ, Andrews NJ, Miller E (2001) Immunity to diphtheria and tetanus in England and Wales. Vaccine 19:167–173CrossRef

33.

Reid PM, Brown D, Coni N, Sama A, Waters M (1996) Tetanus immunization in the elderly population. J Accid Emerg Med 13:184–185PubMed

34.

Symeonidis N, Symeonidis C, Soulioi E, Houiazi E, Diza E, Symeonidis A, Antoniadis A (2003) Serological survey of immunity to tetanus in adult population of Northern Halkidiki, Greece. Eur J Epidemiol 18:1147–1152CrossRefPubMed

35.

Aue A, Hennig H, Krüger S, Closius B, Kirchner H, Seyfarth M (2003) Immunity against diphtheria and tetanus in German blood donors. Med Microbiol Immunol 192:93–97PubMed

36.

Stark K, Schonfeld C, Barg J, Molz B, Vornwald A, Bienzle U (1999) Seroprevalence and determinants of diphtheria, tetanus, and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine 17:844–850CrossRefPubMed

37.

Ozturk A, Gokahmetoglu A, Erdem F, Misguroglu AS (2003) Tetanus antitoxin levels among adults over 40 years of age in Central Anatolia, Turkey. Clin Microbiol Infect 9:33–38

38.

Soyletir G, Yagci A, Topkaya A, Ciragil P (1999) Detection of antitetanus antibodies in Turkish population. Trop Doct 29:161–163PubMed

39.

Redwan el-RM, Al-Awady MK (2002) Prevalence of tetanus immunity in Egyptian population. Hum Antibodies 11:55–59PubMed

40.

Pepersack T, Turneer M, De Breucker S, Stubbe M, Beyer I (2005) Tetanus immunization among geriatric hospitalized patients. Eur J Clin Microbiol Infect Dis 24:495–496CrossRefPubMed

41.

de Melker HE, van den Hof S, Berbers GAM, Nagelkerke NJD, Rümke HJ, Conyn-van Spaendonck MAE (2000) A population-based study on tetanus antitoxin levels in Netherlands. Vaccine 18:100–108CrossRef

Title: Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups
Authors: K. Caglar
R. Karakus
C. Aybay
Publication date: 01-08-2005
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-005-1372-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2005

Two cases of pericarditis associated with blood culture-positive meningococcal septicemia

Necrotizing cervical lymphadenitis due to disseminated Histoplasma capsulatum infection

Diagnostic value of bacterial stool cultures and viral antigen tests based on clinical manifestations of acute gastroenteritis in pediatric patients

Evaluation of non-automated techniques for phenotypic detection of VanA-type Staphylococcus aureus

Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test

Giardia surveillance in Scotland, 1988–2003

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials